Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions
- 5 October 2018
- Vol. 124 (24), 4601-4609
- https://doi.org/10.1002/cncr.31769
Abstract
Despite few effective therapies, only a small percentage of patients diagnosed with myelodysplastic syndromes (MDS) in the United States are enrolled in prospective, interventional clinical trials. MDS‐specific barriers to trial accrual include a high frequency of elderly patients with comorbid conditions, atypical disease features and uncertainty regarding the diagnosis (because other nonclonal processes also can cause dysplasia and cytopenias), a history of another nonmyeloid neoplasm resulting in therapy‐related MDS, rapid disease recurrence after allogeneic stem cell transplantation, and an arbitrary division between MDS and acute myeloid leukemia. In addition, barriers to accrual that are common to other oncology populations, such as difficulty traveling to clinical trial enrollment sites and narrow trial eligibility criteria, also prevent patients with MDS from enrolling in studies. Collectively these barriers must be assessed systematically, and creative solutions are needed to improve outcomes for this needy patient population.Keywords
This publication has 66 references indexed in Scilit:
- Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidineLeukemia, 2011
- Outcome of patients with myelodysplastic syndrome after failure of decitabine therapyCancer, 2010
- Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician SurveysJNCI Journal of the National Cancer Institute, 2008
- Multi-Institutional Phase I Trials of Anticancer AgentsJournal of Clinical Oncology, 2008
- The Tuskegee Legacy Project: Willingness of Minorities to Participate in Biomedical ResearchJournal of Health Care for the Poor and Underserved, 2006
- Systematic Review of Barriers to the Recruitment of Older Patients With Cancer Onto Clinical TrialsJournal of Clinical Oncology, 2005
- Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndromeLeukemia, 2004
- Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago seriesBlood, 2003
- Is this “MDS” or not?Cancer Genetics and Cytogenetics, 2001
- The Hallmarks of CancerCell, 2000